Guggenheim downgraded Amicus (FOLD) to Neutral from Buy on the pending acquisition by BioMarin (BMRN) for $14.50 per share.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FOLD:
- Midday Fly By: SoftBank buying DigitalBridge, Verisk drops AccuLynx deal
- Amicus Therapeutics: Acquisition Premium Caps Upside, Driving Neutral Stance at BioMarin’s $14.50 Offer Price
- Amicus downgraded to Market Perform from Outperform at Leerink
- BioMarin price target raised to $100 from $80 at Truist
- Arcellx initiated, Cummins upgraded: Wall Street’s top analyst calls